Nutrigenomics firm in talks with leading food firms

Leading food and drink manufacturers are in discussions with nutrigenomics firm WellGen about using an ingredient beneficially affecting the expression of genes associated with inflammation, a key factor in the development of chronic diseases.

The black tea extract, the subject of human trials conducted last year, was developed via a biotechnology screening process that identifies food and plant extracts that regulate gene expression, said chief executive Kathleen Mullinix.

WellGen, which is backed by investors including Danisco Ventures, is focusing on proprietary ingredients. However, it also plans to generate revenue by allowing food companies to test their ingredients using its patented screening process to see how they affected the expression of genes associated with other diseases, said Mullinix.

However, speaking at the Nutracon Europe conference on Friday (June 15), Mullinix said that it was important to make a distinction between nutrigenomics and what personalised nutrition or ‘nutrigenetics’ firms were offering.

She said: “Nutrigenetics and ‘DNA diets’ are about identifying mutations [genetic variations between individuals] that give rise to differing responses to nutrients, and then offering dietary advice. Nutrigenomics is about genes we all have in common. There simply isn’t enough knowledge out there yet to offer personalised dietary advice, even if long-term that may well be possible.”

Fears that WellGen was in the business of ‘shutting off’ genes or interfering with the immune system were unfounded, she insisted. “We’re not going after a sparrow with a cannon here. We’re not trying to cause more problems than we solve.”

Longer term, WellGen was also exploring ingredients that focused on cognition and heart health, she said. “We’re convinced that this is a fabulous market opportunity.”